Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of April 2018, with the report signed on April 6, 2018. The registrant is a foreign private issuer based in Tel-Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a periodic disclosure regarding corporate governance and does not contain financial statements.
Material Changes
- Board Resignation: On April 4, 2018, the company received notice of the resignation of Mr. Ran Nussbaum from his position as a director, effective immediately.
- Reason for Departure: Mr. Nussbaum cited a need to reduce the number of boards on which he serves due to commitments to other companies.
- Relationship Status: The filing explicitly states that Mr. Nussbaum has no disagreements with the Board, management, or the registrant's policies.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves solely to disclose the director's resignation and incorporates the report by reference into existing registration statements (Form F-3 and Form S-8).
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Mr. Nussbaum's immediate resignation.
- Confirm whether the resignation impacts any ongoing regulatory filings or registration statements referenced in the document.
- Check for subsequent filings to determine if a replacement director was appointed.